Citius Oncology, Inc.
CTOR · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,925 | $4,240 | $3,428 | $0 |
| G&A Expenses | $15,648 | $7,881 | $1,429 | $0 |
| SG&A Expenses | $15,648 | $7,881 | $1,429 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20,573 | $12,121 | $4,857 | $0 |
| Operating Income | -$20,573 | -$12,121 | -$4,857 | $0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$10 |
| Pre-Tax Income | -$20,573 | -$12,121 | -$4,857 | -$10 |
| Tax Expense | $576 | $576 | $576 | $0 |
| Net Income | -$21,149 | -$12,697 | -$5,433 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.19 | -0.076 | -0.001 |
| % Growth | -57.9% | -149% | -6,258.3% | – |
| EPS Diluted | -0.3 | -0.19 | -0.076 | -0.001 |
| Weighted Avg Shares Out | 71,552 | 89,480 | 90,160 | 81,400 |
| Weighted Avg Shares Out Dil | 71,552 | 89,480 | 90,160 | 81,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,432 | $493 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20,573 | -$12,121 | -$4,857 | -$10 |
| % Margin | – | – | – | – |